tbuckley/cabot-search huggingface dataset:
Coexistent Diabetes Is Associated With the Presence of Adverse Phenotypic Features in Patients With Hypertrophic Cardiomyopathy
Authors: Nicholas Jex, Amrit Chowdhary, Sharmaine Thirunavukarasu, Henry Procter, Anshuman Sengupta, Pavithra Natarajan, Sindhoora Kotha, Ana-Maria Poenar, Peter Swoboda, Hui Xue, Richard M. Cubbon, Peter Kellman, John P. Greenwood, Sven Plein, Stephen Page, Eylem Levelt
Journal: Diabetes Care (2022)

Type 2 diabetes mellitus (T2DM) is associated with worsened clinical outcomes in hypertrophic cardiomyopathy (HCM) patients. We sought to investigate whether HCM patients with T2DM comorbidity exhibit adverse cardiac alterations in myocardial energetics, function, perfusion, or tissue characteristics.A total of 55 participants with concomitant HCM and T2DM (HCM-DM) (n = 20) or isolated HCM (n = 20) and healthy volunteers (HV) (n = 15) underwent 31P-MRS and cardiovascular MRI. The HCM groups were matched for HCM phenotype.Mean ± SD European Society of Cardiology sudden cardiac death risk scores were comparable between the HCM groups (HCM 2.2 ± 1.5%, HCM-DM 1.9 ± 1.2%; P = not significant), and sarcomeric mutations were equally common. HCM-DM patients had the highest median NT-proBNP levels (HV 42 ng/L [interquartile range 35-66], HCM 298 ng/L [157-837], HCM-DM 726 ng/L [213-8,695]; P < 0.0001). Left ventricular (LV) ejection fraction, mass, and wall thickness were similar between the HCM groups. HCM-DM patients displayed a greater degree of fibrosis burden with higher scar percentage and lower global longitudinal strain compared with HCM patients. PCr/ATP (the relative concentrations of phosphocreatine and ATP) was significantly lower in the HCM-DM group than in both HCM and HV (HV 2.17 ± 0.49, HCM 1.93 ± 0.38, HCM-DM 1.54 ± 0.27; P = 0.002). In a similar pattern, stress myocardial blood flow was significantly lower in the HCM-DM group than in both HCM and HV (HV 2.06 ± 0.42 mL/min/g, HCM 1.74 ± 0.44 mL/min/g, HCM-DM 1.39 ± 0.42 mL/min/g; P = 0.002).We show for the first time that HCM-DM patients display greater reductions in myocardial energetics, perfusion, and contractile function and higher myocardial scar burden and serum NT-proBNP levels compared with patients with isolated HCM despite similar LV mass and wall thickness and presence of sarcomeric mutations. These adverse phenotypic features may be important components of the adverse clinical manifestation attributable to a combined presence of HCM and T2DM.
Human Liver Organoids with myeloid lineages model the multi-cellular crosstalk in Non-Alcoholic Steatohepatitis
Authors: Milad Rezvani, Kyle Lewis, Kentaro Iwasawa, Yuqi Cai, Yuka Milton, Masaki Kimura, RanRan Zhang, Praneet Chaturvedi, Takanori Takebe
Journal: Journal of Hepatology (2022)
Bulevirtide is broadly active against all HDV genotypes expressing envelopes from HBV genotypes A-H and a large panel of clinical isolates
Authors: Savrina Manhas, Bin Han, Simin Xu, Lindsey May, Dong Han, Tahmineh Yazdi, Silvia Chang, Thomas Aeschbacher, Rishi Aryal, Ross Martin, Yang Liu, Roberto Mateo, Vithika Suri, Dmitry Manuilov, John F. Flaherty, Julius Hollnberger, Stephan Urban, Tomas Cihlar, Evguenia S Svarovskaia, Hongmei Mo
Journal: Journal of Hepatology (2022)
VIR-2218 plus VIR-3434 combination therapy reduces hepatitis B virus surface antigen levels in vivo
Authors: Julia Noack, Jonathan Gall, Hasan Imam, Yesseinia Anglero-Rodriguez, Vasant Jadhav, Michael A. Schmid, Anna Bakardjiev, Lisa A. Purcell, Christy Hebner, Florian Lempp
Journal: Journal of Hepatology (2022)
Covered TIPS reduces the risk of further decompensation: results from an individual patient data meta-analysis of 3924 patients with cirrhosis
Authors: Hélène Larrue, Pol Olivas, Yong Lv, Guohong Han, Theresa Bucsics, Thomas Reiberger, Tilman Sauerbruch, Virginia Hernandez-Gea, Dominique Thabut, Marika Rudler, Jean Marie Peron, Gennaro D’Amico, Juan Carlos Garcia Pagan, Christophe Bureau
Journal: Journal of Hepatology (2022)
Treatment with Bulevirtide in patients with chronic HBV/HDV co-infection. Safety and efficacy at month 18 in real-world settings
Authors: Victor de Lédinghen, Sophie Metivier, Edouard Bardou-Jacquet, Marie-Noëlle Hilleret, Veronique Loustaud-Ratti, Nathalie Ganne-Carrié, Bruno Roche, Isabelle Fouchard Hubert, Anne Gervais, Anne Minello Franza, Tarik Asselah, Christiane Stern, Jérôme Dumortier, Xavier Causse, Dominique Roulot, Frederic Heluwaert, Leon Muti, Isabelle Rosa, Valérie Canva, Dominique Larrey, Caroline Lascoux-Combe, Juliette Foucher
Journal: Journal of Hepatology (2022)
B cell reactivation in autoimmune hepatitis after immunosuppression withdrawal
Authors: Elena Perpinan, George Koutsoudakis, Laura Patricia Llovet, Thais Leonel, Mar Riveiro Barciela, Montserrat García-Retortillo, Mercé Roget, Alberto Sanchez-Fueyo, Maria Carlota Londoño
Journal: Journal of Hepatology (2022)
The pan-PPAR agonist lanifibranor improves markers of cardiometabolic health in patients with NASH independent of weight change
Authors: Michael Cooreman, Sven Francque, Martine Baudin, Philippe Huot-Marchand, Lucile Dzen, Jean-Louis Junien, Pierre Broqua, Manal Abdelmalek
Journal: Journal of Hepatology (2022)
Effect of long-term dietary intervention on liver pathology and markers of hepatocellular senescence in the GAN diet-induced obese mouse model of NASH
Authors: Kristoffer Voldum-Clausen, Denise Oró, Martin Rønn Madsen, Mathias Flensted-Jensen, Cecilie Holmegaard Andersen, Steen Larsen, Henrik B. Hansen, Michael Feigh
Journal: Journal of Hepatology (2022)
Effectiveness of voxilaprevir/velpatasvir/sofosbuvir in hepatitis C patients previously treated with direct-acting antiviral agents (DAA)
Authors: Christiana Graf, Julia Dietz, Beat Müllhaupt, Peter Buggisch, Jörn Schattenberg, Christoph Antoni, Stefan Mauss, Elena Durmashkina, Claus Niederau, Thomas Discher, Julian Schulze zur Wiesch, Tobias Müller, Thomas Berg, Christoph Neumann-Haefelin, Christoph Berg, Stefan Zeuzem, Christoph Sarrazin
Journal: Journal of Hepatology (2022)
Mitochondrial hyperactivation determines a transferable protective gut microbiota profile in metabolic-associated fatty liver disease development
Authors: María Juárez-Fernández, Naroa Goikoetxea, David Porras, María-Victoria García-Mediavilla, Héctor Rodríguez, Esther Nistal, Susana Martínez-Flórez, Mercedes Rincón, Marta Varela-Rey, Javier González-Gállego, Leticia Abecia, Juan Anguita, María Luz Martínez-Chantar, Sonia Sánchez-Campos
Journal: Journal of Hepatology (2022)
Characterizing of hepatitis B virus serum RNA kinetics during TDF plus pegylated interferon alfa-2a with and without nucleic acid polymers
Authors: Leeor Hershkovich, Louis Shekhtman, Michel Bazinet, Mark Anderson, Mary Kuhns, Gavin Cloherty, Scott Cotler, Andrew Vaillant, Harel Dahari
Journal: Journal of Hepatology (2022)
NLRP3 inflammasome dependent cell death in myeloid cells drives liver inflammation and fibrosis in murine steatohepatitis
Authors: Benedikt Kaufmann, Agustina Reca, Aleksandra Leszczynska, Andre D. Kim, Laela M. Booshehri, Helmut Friess, Daniel Hartmann, Lori Broderick, Hal M. Hoffman, Ariel Feldstein
Journal: Journal of Hepatology (2022)
The PNPLA3 (rs738409) G/G-genotype is associated with presence of NASH and increased long-term risk of cirrhosis in NAFLD
Authors: Magnus Holmer, Robin Zenlander, Axel Wester, Mattias Ekstedt, Patrik Nasr, Stergios Kechagias, Stefano Romeo, Per Stal, Hannes Hagström
Journal: Journal of Hepatology (2022)
P2Y12 inhibitor clopidogrel inhibits renal fibrosis by blocking macrophage-to-myofibroblast transition
Authors: Junzhe Chen, Ying Tang, Yu Zhong, Biao Wei, Xiao-Ru Huang, Patrick Ming-Kuen Tang, Anping Xu, Hui-yao Lan
Journal: Molecular Therapy (2022)

Clopidogrel, a P2Y12 inhibitor, is a novel anti-fibrosis agent for chronic kidney disease (CKD), but its mechanisms remain unclear, which we investigated by silencing P2Y12 or treating unilateral ureteral obstruction (UUO) in LysM-Cre/Rosa Tomato mice with clopidogrel in vivo and in vitro. We found that P2Y12 was significantly increased and correlated with progressive renal fibrosis in CKD patients and UUO mice. Phenotypically, up to 82% of P2Y12-expressing cells within the fibrosing kidney were of macrophage origin, identified by co-expressing CD68/F4/80 antigens or a macrophage-lineage-tracing marker Tomato. Unexpectedly, more than 90% of P2Y12-expressing macrophages were undergoing macrophage-to-myofibroblast transition (MMT) by co-expressing alpha smooth muscle actin (α-SMA), which was also confirmed by single-cell RNA sequencing. Functionally, clopidogrel improved the decline rate of the estimated glomerular filtration rate (eGFR) in patients with CKD and significantly inhibited renal fibrosis in UUO mice. Mechanistically, P2Y12 expression was induced by transforming growth factor β1 (TGF-β1) and promoted MMT via the Smad3-dependent mechanism. Thus, silencing or pharmacological inhibition of P2Y12 was capable of inhibiting TGF-β/Smad3-mediated MMT and progressive renal fibrosis in vivo and in vitro. In conclusion, P2Y12 is highly expressed by macrophages in fibrosing kidneys and mediates renal fibrosis by promoting MMT via TGF-β/Smad3 signaling. Thus, P2Y12 inhibitor maybe a novel and effective anti-fibrosis agent for CKD.
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma
Authors: Mathew Vithayathil, Antonio D’Alessio, Arndt Weinmann, Peter Galle, Claudia Angela Maria Fulgenzi, Petros Fessas, Dominik Bettinger, Bertram Bengsch, Arndt Vogel, Lorenz Balcar, Bernhard Scheiner, Mahvish Muzaffar, Suneetha Amara, Ambreen Muhammed, Abdul Rafeh Naqash, Nicola Personeni, Tiziana Pressiani, Antonella Cammarota, Matthias Pinter, Alessio Cortellini, Lorenza Rimassa, David J. Pinato, Rohini Sharma
Journal: Journal of Hepatology (2022)
Detection of highly variable RNA-containing viral particles on CNT-based electrochemical impedimetric DNA-nanosensors
Authors: Andrei Babenka, Victor Hryharovich, Halina Grushevskaya, Igor Lipnevich, Nina Krylova, Elena Lebedeva, Uladzimir Davydau, Svetlana Marchuk, Dmitry Borisovets, Sergei Zhavoronok
Journal: Journal of Hepatology (2022)
Textbook outcome after major hepatectomy for perihilar cholangiocarcinoma-definitions and influencing factors
Authors: Christian Benzing, Lena Haiden, Felix Krenzien, Alexa Mieg, Annika Wolfsberger, Cecilia Atik, Nora Nevermann, Uli Fehrenbach, Wenzel Schöning, Moritz Schmelzle, Johann Pratschke
Journal: Journal of Hepatology (2022)
Real-world prevalence of metabolic associated fatty liver disease (MAFLD) and fibrotic-non-alcoholic steatohepatitis (NASH) in patients with obesity (PwO) in an outpatient specialist clinic in Italy
Authors: Federico Ravaioli, Maria Letizia Petroni, Francesca Marchignoli, Laura Leoni, Giulia Bocedi, Federica Sacilotto, Valentino Osti, Dorina Mita, Francesca Barbanti, Lucia Brodosi, Giulio Marchesini Reggiani, Loris Pironi
Journal: Journal of Hepatology (2022)
Nutrition state of science and dementia prevention: recommendations of the Nutrition for Dementia Prevention Working Group
Authors: Hussein N Yassine, Cécilia Samieri, Gill Livingston, Kimberly Glass, Maude Wagner, Christy Tangney, Brenda L Plassman, M Arfan Ikram, Robin M Voigt, Yian Gu, Sid O'Bryant, Anne Marie Minihane, Suzanne Craft, Howard A Fink, Suzanne Judd, Sandrine Andrieu, Gene L Bowman, Edo Richard, Benedict Albensi, Emily Meyers, Serly Khosravian, Michele Solis, Maria Carrillo, Heather Snyder, Francine Grodstein, Nikolaos Scarmeas, Lon S Schneider
Journal: The Lancet Healthy Longevity (2022)
Glycine ameliorates paracetamol-induced liver injury in non-alcoholic fatty liver disease by supporting glutathione biosynthesis
Authors: Alia Ghrayeb, Shani Drucker, Bella Agranovich, Daniel Peled, Oren Rom, Ifat Abramovich, Sara Fernandes, Natan Weissman, Jonatan Fernandez Garcia, James Traylor, Chen Eugene, Eyal Gottlieb, Inbal Mor
Journal: Journal of Hepatology (2022)
NASH patient’s itinerary: Comparison of strategies for screening, referring and management
Authors: Manuel Romero Gomez, Yolanda Sánchez, Silvia García Rey, Francisco Javier Atienza Martín, Pablo Remon, Carmen Lara Romero, María C. Roque-Cuéllar, Inmaculada Dominguez, Ioanna-Panagiota Kalafati, Sabine Kahl, Pedro Pablo García-Luna, Jörn Schattenberg, Michael Roden, George Dedoussis, Jeffrey Lazarus
Journal: Journal of Hepatology (2022)
Correlations of 2D-Shear wave and transient elastography liver stiffness measurements in patients with non-alcoholic fatty liver disease
Authors: Dimitrios Karagiannakis, Georgios Markakis, Dimitra Lakiotaki, Elisavet Michailidou, Paraskevi Fytili, Evangelos Cholongitas, Ioannis Vlachogiannakos, George Papatheodoridis
Journal: Journal of Hepatology (2022)
Machine learning encoding of liver biopsy images enables prediction of molecular measurements in a NASH F3/F4 fibrosis clinical cohort
Authors: Michael D. Bereket, Francesco Paolo Casale, Rohit Loomba, Arun Sanyal, Stephen Harrison, Zobair Younossi, Catherine Jia, David Lopez, Li Li, Robert Myers, David Breckinridge, Andrew Billin, Eilon Sharon, Matthew Albert, Theofanis Karaletsos, Daphne Koller
Journal: Journal of Hepatology (2022)
Effect of Social Needs Case Management on Hospital Use Among Adult Medicaid Beneficiaries
Authors: Daniel M. Brown, Elizabeth A. Hernandez, Sara Levin, Mathijs De Vaan, Mi-Ok Kim, Chris Lynch, Anna Roth, Amanda L. Brewster
Journal: Annals of Internal Medicine (2022)

Case management programs assisting patients with social needs may improve health and avoid unnecessary health care use, but little is known about their effectiveness.This large-scale study assessed the population-level impact of a case management program designed to address patients' social needs.Single-site randomized encouragement design with administrative enrollment from an eligible population and intention-to-treat analysis. Study participants were enrolled between August 2017 and December 2018 and followed for 1 year. (ClinicalTrials.gov: NCT04000074).Contra Costa County, an economically and culturally diverse community in the San Francisco Bay Area.57 972 randomized enrollments of adult Medicaid patients at elevated risk for health care use (top 15%) to the intervention or control group.Enrollees were offered 12 months of social needs case management, which provided more intensive services to patients with higher demonstrated needs.Medical use was measured via emergency department (ED) visits and inpatient admissions, some of which were classified as avoidable.Participants in the intervention group visited the ED at ratios of 0.96 (95% CI, 0.91 to 1.00) for all visits and 0.97 (CI, 0.92 to 1.03) for avoidable visits relative to the control group. The intervention group was hospitalized at ratios of 0.89 (CI, 0.81 to 0.98) for all admissions and 0.72 (CI, 0.55 to 0.88) for avoidable admissions.Only 40% of the intervention group engaged with the program. The program was in continual development during the trial period.Although social needs case management programs may reduce health care use, these savings may not cover full program costs. More work is needed to identify ways to increase patient uptake and define characteristics of successful programs.Contra Costa Health Services via the Medicaid waiver program.
Quantitative magnetic resonance cholangiopancreatography identifies features of ductal disease change in primary sclerosing cholangitis: a prospective observational cohort study
Authors: Palak Trivedi, Katherine Arndtz, Nadir Abbas, Alison Telford, Liam Young, Rajarshi Banerjee, Peter Eddowes, Kartik Jhaveri, Gideon Hirschfield
Journal: Journal of Hepatology (2022)
Long-term outcomes of liver transplantation (LT) using grafts from donors with active and chronic hepatitis B virus (HBV) infection: multi-center cohort study
Authors: Sujin Gang, YoungRok Choi, Boram Lee, Kyung Chul Yoon, Su young Hong, Sanggyun Suh, Eui Soo Han, Suk Kyun Hong, Hae Won Lee, Jai Young Cho, Nam-Joon Yi, Kwang-Woong Lee, Kyung-Suk Suh
Journal: Journal of Hepatology (2022)
Performance of a p-SWE method implemented on a new ultrasound system for predicting advanced liver fibrosis
Authors: Alexandru Popa, Roxana Sirli, Alina Popescu, Andreea Borlea, Felix Bende, Victor Baldea, Raluca Lupusoru, Camelia Foncea, Radu Cotrau, Pascu Ariana, Ioan Sporea
Journal: Journal of Hepatology (2022)
The ubiquitin-like modifier FAT10 is upregulated during NASH and impairs PPAR-alpha activity
Authors: Ludivine Clavreul, Alexia Cotte, Lucie Bernard, Joel Haas, Nathalie Hennuyer, An Verrijken, Luc Van Gaal, Sven Francque, Guillaume Lassailly, Bart Staels, Réjane Paumelle
Journal: Journal of Hepatology (2022)
RELB activation drives tumour aggressiveness and predicts prognosis in hepatocellular carcinoma
Authors: Luisa Nader, Federico Nichetti, Anna-Lena Scherr, Christin Elssner, Dirk Ridder, Sarah Fritzsche, Sofia Weiler, Thomas Albrecht, Annika Kessler, Nathalie Schmitt, Felix Korell, Liangtao Ye, Toni Urbanik, Christoph Heilig, Mohammad Rahbari, Lydia Brandl, Christoph Springfeld, Thomas Longerich, Henning Schulze-Bergkamen, Dirk Jäger, Stefan Fröhling, Peter Schirmacher, Beate Straub, Achim Weber, Mathias Heikenwälder, Enrico de Toni, Benjamin Goeppert, Stephanie Roessler, Kai Breuhahn, Bruno Köhler
Journal: Journal of Hepatology (2022)
Fastigial nuclei surgical damage and focal midbrain disruption implicate PAG survival circuits in cerebellar mutism syndrome
Authors: Samuel S McAfee, Silu Zhang, Ping Zou, Heather M Conklin, Darcy Raches, Giles Robinson, Amar Gajjar, Raja Khan, Paul Klimo, Zoltan Patay, Matthew A Scoggins
Journal: Neuro-Oncology (2022)

Abstract Background Pediatric postoperative cerebellar mutism syndrome (CMS) is a rare but well-known complication of medulloblastoma (Mb) resection with devastating effects on expressive language, mobility, cognition, and emotional regulation that diminishes quality of life for many Mb survivors. The specific anatomical and neuronal basis of CMS remains obscure. We address this issue by identifying patterns of surgical damage and secondary axonal degeneration in Mb survivors with CMS. Methods Children with Mb deemed high risk for CMS based on intraventricular location of the tumor had T1 images analyzed for location(s) of surgical damage using a specially developed algorithm. We used three complementary methods of spatial analysis to identify surgical damage linked to CMS diagnosis. Magnetization transfer ratio (MTR) images were analyzed for evidence of demyelination in anatomic regions downstream of the cerebellum, indicating neuronal dysfunction. Results Spatial analyses highlighted damage to the fastigial nuclei and their associated cerebellar cortices as the strongest predictors of CMS. CMS-related MTR decrease was greatest in the ventral periaqueductal gray (PAG) area and highly consistent in the left red nucleus. Conclusion Our evidence points to disruption of output from the fastigial nuclei as a likely causal trigger for CMS. We propose that core CMS symptoms result from a disruption in the triggering of survival behaviors regulated by the PAG, including the gating of vocalization and volitional movement. The fastigial nuclei provide the densest output to the PAG from the cerebellum, thus sparing these structures may provide a greater likelihood of CMS prevention.
Dynamic multiomics analysis characterizes circulating molecular determinants associated with poor outcome in patients with severe alcoholic hepatitis
Authors: Jaswinder Maras, Adil Bhat, Nupur Sharma, Manisha Yadav, Gaurav Tripathi, Babu Mathew, Vasundhra Bindal, Shvetank Sharma, Rakhi Maiwall, Shiv Kumar Sarin
Journal: Journal of Hepatology (2022)
Neutrophil gelatinase-associated lipocalin predicts response to terlipressin and albumin in patients with hepatorenal syndrome
Authors: Carmine Gabriele Gambino, Matteo Stenico, Marta Tonon, Alessandra Brocca, Valeria Calvino, Simone Incicco, Chiara Cosma, Martina Zaninotto, Patrizia Burra, Umberto Cillo, Mario Plebani, Paolo Angeli, Salvatore Piano
Journal: Journal of Hepatology (2022)
Comparative performance analysis between manual and automatic RNA extraction to quantify HDV RNA by RoboGene 2.0 kit in untreated and bulevirtide-treated HDV patients
Authors: Sara Colonia Uceda Renteria, Alessandro Loglio, Marta Borghi, Dana Sambarino, Riccardo Perbellini, Floriana Facchetti, Sara Monico, Elisabetta Degasperi, Ferruccio Ceriotti, Pietro Lampertico
Journal: Journal of Hepatology (2022)
No effect of HBsAg positivity on antibody response after COVID-19 vaccine
Authors: Ganbolor Jargalsaikhan, Enkhtuul Batbold, Delgersaikhan Zulkhuu, Oyungerel Lkhagva-Ochir, Uurtsaikh Baatarsuren, Myagmarjav Budeebazar, Khatanzul Ganbold, Sumiya Byambabaatar, Byambasuren Ochirsum, Munkhzaya Munkhbaatar, Purevjargal Bat-Ulzii, Bishguurmaa Renchindorj, Andreas Bungert, Naranbaatar Dashdorj, Katy Shaw-Saliba, Irini Sereti, Sally Hunsberger, Renee Ridzon, Naranjargal Dashdorj
Journal: Journal of Hepatology (2022)
Sustainability of humoral immunity induced by the SARS-CoV-2 vaccine and response to booster dose among Liver Transplant recipients
Authors: Liane Rabinowich, Ayelet Grupper, Inbal Houri, Sharon Levy, Merav Ben-Yehoyada, Tami Halperin, Oren Shibolet, Helena Katzman
Journal: Journal of Hepatology (2022)
Efficacy and safety of finite 48-week treatment with the siRNA JNJ-3989 and the capsid assembly modulator (CAM-N) JNJ-6379 in HBeAg negative virologically suppressed (VS) chronic hepatitis B (CHB) patients: results from REEF-2 study
Authors: Kosh Agarwal, Maria Buti, Florian van Bömmel, Pietro Lampertico, Ewa Janczewska, Marc Bourliere, Thomas Vanwolleghem, Oliver Lenz, Thierry Verbinnen, Thomas Kakuda, Cristina Mayer, John Jerzorwski, Maria Beumont-Mauviel, Ronald Kalmeijer, Michael Biermer, Isabelle Lonjon-Domanec
Journal: Journal of Hepatology (2022)
Multispectral analysis of liver biopsies from patients with chronic hepatitis C reveals unique macrophage phenotypes and spatial interactions associated with fibrosis progression
Authors: Omar Saldarriaga, Santhoshi Krishnan, Morgan Oneka, Arvind Rao, Joseph Gosnell, Daniel Millian, Timothy Wanninger, Jingjing Jiao, Laura Beretta, Heather Stevenson
Journal: Journal of Hepatology (2022)
Hepatitis B virus antigen reduction effect of RO7049389 plus NUC with/without Peg-IFN in chronic hepatitis B patients
Authors: Jinlin Hou, Edward J Gane, Wenhong Zhang, Jiming Zhang, Man-Fung Yuen, Tien Huey Lim, Rozalina Balabanska, Qing Xie, Piyawat Komolmit, Xieer Liang, Wen Zhang, Xue Zhou, Zenghui Xue, Miriam Triyatni, Ethan Chen, Yuchen Zhang, Qingyan Bo
Journal: Journal of Hepatology (2022)
Validation of the new 2021 EASL algorithm for the non-invasive diagnosis of advanced liver fibrosis in non-alcoholic fatty liver disease
Authors: Clémence M. Canivet, Adrien Lannes, Charlotte Costentin, Adele Delamarre, Nathalie Sturm, Frédéric Oberti, Thomas Decaens, Marie Irles-Depe, Isabelle Fouchard, Paul Hermabessière, Justine Barthemon, Victor de Lédinghen, Jerome Boursier
Journal: Journal of Hepatology (2022)
Retrospective AI-based measurement of NASH histology (AIM-NASH) analysis of biopsies from Phase 2 study of Resmetirom confirms significant treatment-induced changes in histologic features of non-alcoholic steatohepatitis
Authors: Stephen Harrison, Janani Iyer, Charles Biddle-Snead, Sara Hoffman, Quang Le, Victoria Mountain, Murray Resnick, Katy Wack, Jim Hennan, Rebecca Taub
Journal: Journal of Hepatology (2022)
Unravelling the circadian transcriptome and epigenome of the human liver
Authors: Atish Mukherji, Frank Jühling, Laurent Mailly, Carla Eller, Katharina Herzog, Cloé Gadenne, Clara Ponsolles, Alexandre Haller, Philippe Baltzinger, Hiroshi Aikata, Michio Imamura, Catherine Schuster, Xiaodong Zhuang, Jacinta Holmes, Jane McKeating, Irwin Davidson, Patrick Pessaux, Joachim Lupberger, Thomas Baumert
Journal: Journal of Hepatology (2022)
The effects of apurimic/apirimidinic endonuclease 1 as a sensitizer to sorafenib in hepatocellular carcinoma
Authors: Mahzeiar Samadaei, Daniel Senfter, Sibylle Madlener, Karolina Uranowska, Christine Hafner, Michael Trauner, Nataliya Rohr-Udilova, Matthias Pinter
Journal: Journal of Hepatology (2022)